Element 1 Corp. and Ballard Power Systems Collaborate on Revolutionary Hydrogen Power Solutions
29.5.2024 14:00:00 EEST | Business Wire | Press release
Element 1 Corp, a pioneer in on-demand hydrogen generation technology, and Ballard Power Systems (NASDAQ: BLDP; TSX: BLDP), have joined forces to accelerate the adoption of sustainable hydrogen energy solutions. This groundbreaking collaboration aims to revolutionize the way we generate and utilize hydrogen for various applications.
Specifically, the joint effort successfully paired Ballard’s FCwave™ 200-kW fuel cell module with Element 1’s M/L18 hydrogen generator (235 kg hydrogen per day), producing high-purity hydrogen in the range of 0.7 to 2.2 barg. This is a major breakthrough, since the typical FCwave™ hydrogen supply pressure range is 3.5 to 6.5 barg. This low-pressure result was achieved with Ballard-developed software modifications to the operation of the FCwave™; no hardware modifications were implemented.
Element 1’s generators produce hydrogen that meets ISO 14687-2019 standards for PEM fuel cells. Using a feedstock comprising methanol mixed with water, the M/L18 hydrogen generator produces hydrogen on demand and at the point of use for a fraction of the cost of compressed or liquid hydrogen. Additionally, the infrastructure and transportation challenges associated with handling compressed and liquid hydrogen are eliminated with methanol/water mix that may be handled, shipped, and stored using the same infrastructure developed over decades for handling other liquid fuels.
Dave Edlund, co-founder and CEO of Element 1 Corp, said, “With a simple software upgrade, any deployed FCwave™ may be coupled to an M/L18 hydrogen generator to achieve immediate savings on operational costs. And if renewable methanol is used, the carbon intensity of the resulting electrical power will be very low.”
About Element 1 Corp
Element 1 Corp. (Bend, Oregon) is a leading developer of advanced hydrogen generation systems supporting the fuel cell industry. Element 1 has developed innovative products that are scalable, reliable, affordable, and provide flexibility allowing for easy integration into customer solutions. With expertise in small-scale reactor design and membrane-based hydrogen purifiers, Element 1 offers solutions for on-site hydrogen generation, grid-independent electrical power generation to support BEV charging and microgrid applications, and mobile (onboard) hydrogen generation (fuel cell electric vehicles). Novel technology is licensed by Element 1 to its partners, enabling the application of technologies across a wide range of products, markets, and applications. For further information please visit www.e1na.com.
About Ballard Power Systems
Ballard Power Systems’ (NASDAQ: BLDP; TSX: BLDP) vision is to deliver fuel cell power for a sustainable planet. Ballard zero-emission PEM fuel cells are enabling the electrification of mobility, including buses, commercial trucks, trains, marine vessels, and stationary power. To learn more about Ballard, please visit www.ballard.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529678952/en/
Contact information
For media inquiries, please contact:
Dave Edlund, Co-Founder and CEO, Element 1 Corp; Phone: (541) 678-0005 Email: dave@e1na.com
Kate (Charlton) Igbalode, VP Corporate Finance & Strategy, Ballard Power Systems; +1.604.453.3939, investors@ballard.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom